

Research Article

Yi Qi Qing Re Gao Attenuates Podocyte Injury and Inhibits Vascular Endothelial Growth Factor Overexpression in Puromycin Aminonucleoside Rat Model

Yongli Zhan,¹ Liping Yang,¹ Yumin Wen,² Huijie Liu,² Haojun Zhang,³ Bin Zhu,³ Wenbing Han,² Yanting Gu,³ Xueyan Sun,² Xi Dong,³ Tingting Zhao,³ Huixia Ma,³ and Ping Li³

¹ Department of Nephrology, Guang'anmen Hospital of China Academy of Traditional Chinese Medical Sciences, No. 5 Beixiange, Xicheng District, Beijing 100053, China

² Beijing University of Chinese Medicine, No. 11 Beisanhuan Donglu, Chaoyang District, Beijing 100029, China

³ Department of Pharmacology, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, No. 2 Yinghua Dongjie, Hepingli, Beijing 100029, China

Correspondence should be addressed to Ping Li; lp8675@163.com

Received 23 January 2014; Revised 24 April 2014; Accepted 26 April 2014; Published 21 May 2014

Academic Editor: Yoshiji Ohta

Copyright © 2014 Yongli Zhan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Proteinuria is the hallmark of chronic kidney disease. Podocyte damage underlies the formation of proteinuria, and vascular endothelial growth factor (VEGF) functions as an autocrine/paracrine regulator. Yi Qi Qing Re Gao (YQQRG) has been used to treat proteinuria for more than two decades. The objective of this study was to investigate the protective effect and possible mechanisms of YQQRG on puromycin aminonucleoside (PAN) rat model. Eighty male Sprague-Dawley rats were randomized into sham group, PAN group, PAN + YQQRG group, and PAN + foscipril group. Treatments were started 7 days before induction of nephrosis (a single intravenous injection of 40 mg/kg PAN) until day 15. 24 h urinary samples were collected on days 5, 9, and 14. The animals were sacrificed on days 3, 10, and 15, respectively. Blood samples and renal tissues were obtained for detection of biochemical and molecular biological parameters. YQQRG significantly reduced proteinuria, elevated serum albumin, and alleviated renal pathological lesions. YQQRG inhibited VEGF-A, nephrin, podocin, and CD2AP mRNA expression and elevated nephrin, podocin, and CD2AP protein levels starting on day 3. In conclusion, YQQRG attenuates podocyte injury in the rat PAN model through downregulation of VEGF-A and restoration of nephrin, podocin, and CD2AP protein expression.

1. Introduction

Clinical and experimental studies indicate that proteinuria is the major risk factor for CKD progression and glomerular sclerosis and also a marker of increased cardiovascular morbidity and mortality [1]. The glomerular filtration of albumin is followed by receptor-mediated endocytosis of the proximal tubular cells, so both the glomerular filtration barrier (GFB) and tubular dysfunction are involved in the initiation of proteinuria, leading to increased excretion of albumin in the urine. Loss of selectivity of GFB to protein filtration, however, is the common final pathway for proteinuric glomerulopathies, independent of the underlying

causes. The GFB is composed of the fenestrated endothelium, the basement membrane, the podocyte, and its slit diaphragm [2]. Increasing evidence suggests that podocytes are the essential determinant of GFB function. Podocytes are highly differentiated cells with finger-like foot processes connecting its adjacent compartments with slit-diaphragm (SD) molecules. The SD is the size-selective permeability barrier for the passage of plasma proteins across the GFB. When podocytes are injured, their cytoskeletal structure and intercellular junctions are damaged, resulting in morphological change called foot process effacement, which leads to proteinuria. Further manifestations are podocyte detachment

from the GBM and glomerular sclerosis [3, 4]. Up to now, the molecular basis of SD structure has been illustrated. Nephlin, encoded by the NPSH1 gene, is a transmembrane glycoprotein, belonging to the immunoglobulin superfamily that functions as the structural backbone of SD. Nephlin consists of eight extracellular Ig domains, followed by a fibronectin type III-like domain, a short transmembrane region, and a cytoplasmic C-terminus. The cysteine in the fibronectin type III-like domain can form disulfide bond with the adjacent nephlin molecule to form a zipper-like structure of SD [5]. Mutations of the nephlin gene results in congenital nephrotic syndrome of the Finnish type (CNF), characterized by massive proteinuria, podocyte foot process effacement, and absence of the slit diaphragm [6, 7]. Nephlin also functions as an intracellular signaling scaffold, which interacts with the adapter protein CD2AP and podocin. The N-terminus of CD2AP contains a Src homology 3 (SH3) domain and functions as an adaptin. CD2AP interacts with podocin and nephlin via its C-terminus, locating its anchor within lipid rafts in order to preserve the functions of the cytoskeleton and SD. Damage to CD2AP directly damages the podocyte cytoskeleton, leading to deformation and disappearance of podocyte and massive proteinuria. In addition, CD2AP can interact with various signaling molecules via its SH3 region and participate in cytoskeleton assembly [7–9]. Yaddanapudi et al. substantiated that CD2AP regulates TGF- β 1-dependent translocation of dentrin from the SD to nucleus and functions as a gatekeeper for reorganization of the podocyte microfilament system and consequent proteinuria [10]. Podocin is encoded by NPSH2 gene and is a new member of the stomatin family of lipid raft-associated proteins. Podocin functions as a supporting protein in the maintenance of the podocyte process and integrity of SD [11]. Other proteins, including Neph1, FAT-1 [12], ZO-1 [13], and podocalyxin [14], are noted in animal mutant models, and mutations of any of these proteins result in massive proteinuria and early postnatal death.

Vascular endothelial growth factor-A (VEGF-A) is an angiogenesis and endothelial survival factor. It is also a critical “cross-talk” protein among the three components of GFB [15]. Podocytes are the major site of VEGF expression in the glomeruli. VEGF-A binds to its receptors VEGFR1 (Flt-1), VEGFR2 (Flk-1), and coreceptors neuropilin 1 and 2. There are three isoforms of VEGF-A that podocytes synthesize: VEGF121, 165, and 189 by alternative mRNA splicing [16]. Sison et al. demonstrated that VEGF regulates slit diaphragm signaling through VEGFR2-nephlin cross-talk [17]. VEGF gain of function downregulates nephlin expression and distorts podocyte morphology, which concurs with the foot process effacement and proteinuria [18–20]. The autocrine VEGF signaling system in podocytes also regulates SD proteins by inducing podocin upregulation and increasing its interaction with CD2AP *in vitro* [16].

YQQRG has been used in Guang’anmen Hospital to treat CKD for more than two decades, previous study demonstrated that YQQRG reduces proteinuria, elevates serum albumin, and decreases serum cholesterol in patients with chronic nephritis [21]. Animal experiments have shown that the formula inhibits extracellular matrix accumulation

in adriamycin nephrosis [22]. However, the mechanism of YQQRG in the treatment of proteinuria remains unknown. Since podocyte injury has been found to be the main pathogenesis of proteinuria, our study investigated whether YQQRG possesses a regulatory effect on podocytopathy and VEGF expression.

2. Materials and Methods

2.1. Drugs and Reagents. YQQRG was manufactured by Guang’anmen Hospital, (certificate number: 98 Beijing Health and Drug number 058). The formula includes Radix Astragali Mongolici (*huang qi*) 72 g, Rhizoma Atractylodis Macrocephalae (*bai zhu*) 54 g, Radix Saposhnikoviae (*fang feng*) 36 g, Flos Lonicerae (*jin yin hua*) 72 g, Fructus Forsythiae Suspensae (*lian qiao*) 72 g, Herba Duchesneae Indicae (*she mei*) 54 g, Hedyotis Diffusa Willd (*bai hua she she cao*) 180 g, Poria Cocos (*fu ling*) 72 g, Rhizoma Alismatis (*ze xie*) 125 g, Herba Leonuri Japonici (*yi mu cao*) 180 g, Rhizoma Imperatae (*bai mao gen*) 180 g, and Rhizoma Dioscoreae Nipponica (*chuan shan long*) 70 g. The herbal medicinals were prepared through a process of decoction, concentration, purification by ethanol precipitation, and sterilization. The final standardized product was 4.5 g crude medicinal per milliliter (Figure 1(a)). Fosinopril sodium tablets (10 mg/tablet) were purchased from Bristol-Myers Squibb Shanghai (Lot number: H19980197).


PAN and podocin monoclonal antibody were purchased from Sigma-Aldrich (St. Louis, MO, USA); nephlin monoclonal antibody was purchased from Santa Cruz Biotech (Santa Cruz, CA, USA); CD2AP and VEGF-A monoclonal antibodies were purchased from Abcam (Cambridge, UK); β -actin monoclonal antibody, goat anti-mouse IgG, and goat anti-rabbit IgG antibodies were purchased from Zhongshan Jinqiao (Shanghai, China); immunohistochemical kit was purchased from Gene Technology Company (Shanghai, China). Other chemicals and reagents were of analytical grade.

2.2. Animals and Experimental Design. Eighty male Sprague-Dawley rats, weighing 90–100 g were purchased from Beijing HFK Bio-Technology Co. Ltd. (Beijing, China, Certificate No. SCXK-(Jing) 2009-0007). All animals were housed at $22 \pm 3^\circ\text{C}$ and $50 \pm 10\%$ humidity, with 12 h light/dark cycle, and were given free access to tap water and standard chow. This study was approved by the Ethics Committee of China-Japan Friendship Hospital and performed in accordance with the Guiding Principles for the Care and Use of Laboratory Animals (No. 2010-A10).

Animals were randomized to four groups after 1 week of adaptive feeding: sham group, PAN group, PAN + YQQRG treatment group (YQQRG, 4 g/kg, 14 times human dosage), and PAN + fosinopril treatment group (1.667 mg/kg, 10 times human dosage). Animals in PAN and both treatment groups were anesthetized with an intraperitoneal injection of 10% chloral hydrate and then received a single intravenous injection of 40 mg/kg PAN through a cannula in the right internal jugular vein within 5 min. Animals in the sham



(a)



(b)

FIGURE 1: Composition of YQQRG and study design. (a) Plants of the components of YQQRG. (b) Time plot of study design.

group were injected with equal volume of saline. All drugs were dissolved in distilled water and given by gastric gavage once daily 7 days before induction of nephrosis until day 15. On days 5, 9, and 14 after PAN injection, the animals were housed individually in metabolic cages, deprived of food and with free access to water. Collections of 24-hour urine were

obtained. Total urinary protein was measured by the Bradford method. Six rats from each group were anesthetized with an intraperitoneal injection of 10% chloral hydrate and sacrificed on days 3, 10, and 15 after PAN injection (Figure 1(b)). Blood samples were taken from the abdominal aorta and serum was separated for measurement of alanine transaminase (ALT),

aspartate aminotransferase (AST), creatinine (Cre), blood urea nitrogen (BUN), total protein (TP), albumin (Alb), total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL), and low density lipoprotein (LDL). Samples were processed using an automatic biochemistry analyzer (RA-1000 CS; Technicon, USA).

2.3. Histological Examination of the Kidney. Sections of kidney were fixed in 10% phosphate buffered formalin solution for 24 h, embedded in paraffin, sectioned at 3 μm slices, and stained with periodic acid-schiff stain. Slices were examined microscopically and photographed (BX-51 Research Microscope system and DP70 Image Acquisition System; Olympus, Japan). For electron microscopy examination, small samples of the right kidney were removed and cut into 1 mm^3 , fixed in 2.5% glutaraldehyde, dehydrated with gradient acetone, embedded with ethoxyline resin Epon 812, sliced by ultrathin slicing machine, and examined by transmission electron microscopy (H-600, Hitachi, Japan).

2.4. Immunohistochemistry. Immunohistochemistry stain of nephrin was conducted following the manufacturer's instructions. Briefly, slices of 3 μm kidney sections were put into 60°C oven for 2 hours. After gradient deparaffinization and rehydration, the slices were immersed in microwave heated 0.01 mol/L citrate buffer at 100°C for retrieval of antigen sites. Endogenous peroxidase activity was quenched by incubation with 3% H_2O_2 . The slices were incubated with nephrin antibody (1:100) at 4°C overnight. After three 5-min washes with PBS, each section was incubated with the secondary antibody at 37°C for 30 min. The visualization of slices was developed with diaminobenzidine (Dako Corp., Carpinteria, CA) and was counterstained with hematoxylin. The semiquantitative analysis of nephrin was determined using the Image-Pro Plus 6.0 image analysis software (Media Cybernetics, Warrendale, PA, USA). Briefly, ten random fields of glomerular under an upright microscope at 400x magnification were outlined and positive staining patterns were identified. The percentage of positive stained area occupying the selected glomeruli was calculated. The analysis was performed with blindness of groups.

2.5. Real-Time Polymerase Chain Reaction (RT-PCR). Total RNA of renal cortex was isolated using total RNA Kit (R6934, Omega Bio-tech Inc., GA, USA) following the manufacturer's instructions. cDNA was synthesized in cDNA Synthesis Kit (KI622, Fermentas International Inc., Canada) according to the manufacturer's instructions. Each PCR was performed in triplicate in a final volume of 20 μL solution: 10 μL of SYBR Green dye, 1 μL of diluted cDNA products, 0.2 μL of each paired primer, and 8.6 μL deionized water. Protocols were as follows: initial denaturation for 10 min at 95°C, followed by 30 cycles (for nephrin, podocin, and VEGF-A) or 32 cycles (for CD2AP and Cyclophilin-B) denaturation for 15 s at 95°C, and extension for 30 s at 60°C (for VEGF-A and Cyclophilin-B) or 58°C (for nephrin, podocin, and CD2AP). The last cycle for dissociation of SYBR Green probe was 15 s at 95°C, 30 s at 60°C, and 15 s at 95°C. Cyclophilin-B was

used as a house-keeping gene as previously reported [23]. Threshold cycle (C_T) values of target genes were measured and normalized to that of Cyclophilin-B and expressed as a relative ratio. The specific primer sequences were nephrin: forward 5'-ATGGGCGCTAAGAGAGTCAC-3' and reverse 5'-CGCAGTCAGGTTTTTCAGACA-3'. Podocin: forward 5'-TCTTGTCTCTCCTCCCTGA-3' and reverse 5'-AGACGGAGGTC AACCTTGTG-3'. CD2AP: forward 5'-GCTGGTGAAAGGTGAACTG-3' and reverse 5'-CATCTCTGTCTTCCGCCTTC-3'. VEGF-A: forward 5'-ACTGGA-CCCTGGCTTTACTGC-3' and reverse 5'-TTGGTGAGGTTTGATCCGCATG-3'. Cyclophilin-B: forward 5'-CCA-TCGTGTCAAGGACTTCAT-3' and reverse 5'-TTG-CCGTCTAGCCAGGAGTCT-3'. The ΔC_T value was determined by subtracting the Cyclophilin-B C_T value of each sample from its respective target C_T . Fold changes of the target gene were equivalent to $2^{-\Delta\Delta C_T}$ [24].

2.6. Western Blot Analysis. Renal cortices were homogenated with lysis buffer and 1x protease inhibitor cocktail in a tissue homogenator (Roche Diagnostics, Indianapolis, IN, USA) and then centrifuged. The supernatant was extracted to measure the concentration of protein. The protein samples were then added in 5x SDS-PAGE loading buffer and were heated at 100°C for 10 min to be denatured. Proteins (80 μg) were separated by 12% SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to an immunoblot polyvinylidene fluoride (PVDF) membrane (Bio-Rad, Hercules, CA, USA). After blocking in PBS/Tween (0.1%) with 5% skim milk for 2 hours, the membrane was incubated with primary antibodies (nephrin antibody 1:500, podocin antibody 1:2000, and CD2AP antibody 1:1000) overnight at 4°C. Target bands were detected using a horseradish peroxidase-conjugated secondary antibody and developed using Pierce enhanced chemiluminescence (ECL) (ThermoScientific, Fisher Scientific, Pittsburgh, PA, USA). Band intensity of nephrin, podocin, CD2AP, and VEGF-A was normalized to that of β -actin and expressed as a relative ratio. Semiquantifications were performed using Image J program (National Institutes of Health, Bethesda, MD, USA).

2.7. Statistical Analysis. Data were presented as means \pm standard deviation (SD) unless otherwise stated. Comparison of measurement data between groups were evaluated by the analysis of variance (ANOVA), followed by Student-Newman-Keuls (SNK) test. P values <0.05 were regarded as statistically significant. All statistical analyses were performed by SPSS 17.0.

3. Results

3.1. YQQRG Attenuated Urinary Protein Excretion in PAN Rats. The 24 h urinary protein level of each group was within normal range before injection of PAN. Urinary protein increased significantly at day 5, peaked at day 9, and slightly decreased at day 14 after PAN injection. There was significant reduction of urinary protein level at days 9 and 14 in YQQRG

TABLE 1: YQQRG elevated serum Alb levels and regulated lipid disorder.

	Time points (day)	Sham	PAN	YQQRG	Fosinopril
ALT (U/L)	3	43.67 ± 3.21	39.33 ± 2.31	32.75 ± 2.75	39.5 ± 2.06
	10	49.6 ± 7.02	43.67 ± 6.41	47.2 ± 9.58	43.0 ± 3.0
	15	42.0 ± 8.85	32.38 ± 7.17	32.33 ± 3.88	39.0 ± 5.14
ASL (U/L)	3	130.2 ± 8.1	119.98 ± 5.19	103.8 ± 7.21	119.67 ± 5.94
	10	100.94 ± 9.15	73.54 ± 7.42	73.43 ± 18.89	71.74 ± 19.83
	15	155.28 ± 27.54	96.71 ± 22.07	122.12 ± 19.39	116.58 ± 16.90
TP (mmol/L)	3	50.6 ± 5.26	49.53 ± 5.0	50.88 ± 6.57	46.98 ± 5.43
	10	49.98 ± 2.44	44.3 ± 3.50*	46.96 ± 3.57	43.02 ± 2.47*
	15	59.61 ± 9.68	49.44 ± 3.79*	53.3 ± 7.32	52.33 ± 2.06*
Alb (g/L)	3	34.03 ± 3.32	31.73 ± 2.68	32.88 ± 3.22	30.73 ± 2.31
	10	32.4 ± 1.42	23.38 ± 2.39*	24.87 ± 3.40*	24.02 ± 3.05*
	15	36.35 ± 4.35	27.06 ± 3.51*	29.16 ± 3.20* [▲]	30.06 ± 2.06* [▲]
BUN (mmol/L)	3	10.18 ± 1.77	10.03 ± 1.59	9.6 ± 1.38	7.48 ± 1.03
	10	5.82 ± 1.57	7.85 ± 0.66	6.73 ± 2.15	5.77 ± 1.40
	15	5.71 ± 1.40	6.33 ± 1.31	6.18 ± 0.73	7.14 ± 1.48
Cre (μmol/L)	3	33 ± 7.94	27.67 ± 5.13	27.0 ± 5.6	16.67 ± 0.47
	10	25.6 ± 1.14	25.6 ± 3.91	26.33 ± 2.89	19.33 ± 1.53
	15	31.17 ± 3.82	27.14 ± 4.34	27.86 ± 5.08	25.28 ± 3.03
TC (mmol/L)	3	2.10 ± 0.07	1.94 ± 0.23	2.15 ± 0.09	2.01 ± 0.26
	10	1.68 ± 0.13	4.95 ± 1.24*	4.25 ± 1.29*	4.27 ± 1.31*
	15	1.87 ± 0.28	5.49 ± 1.47*	4.11 ± 1.14* [▲]	3.78 ± 0.98* [▲]
TG (mmol/L)	3	0.57 ± 0.13	0.18 ± 0.03	0.33 ± 0.01	0.15 ± 0.02
	10	0.74 ± 0.13	5.26 ± 1.76*	1.63 ± 0.59 [▲]	1.43 ± 0.41 [▲]
	15	0.39 ± 0.14	2.24 ± 1.44*	0.60 ± 0.36 [▲]	0.51 ± 0.21 [▲]
HDL (mmol/L)	3	1.54 ± 0.23	1.63 ± 0.21	2.16 ± 0.10	1.75 ± 0.19
	10	1.41 ± 0.1	3.52 ± 0.63*	3.37 ± 0.65*	2.92 ± 0.62*
	15	1.52 ± 0.15	4.06 ± 0.7*	3.19 ± 0.74 [▲]	3.0 ± 0.62 [▲]
LDL (mmol/L)	3	0.84 ± 0.14	0.89 ± 0.13	1.1 ± 0.12	0.9 ± 0.10
	10	0.63 ± 0.11	2.38 ± 0.67*	2.51 ± 0.68*	1.98 ± 0.48*
	15	0.84 ± 0.12	2.18 ± 0.83*	1.77 ± 0.63* [▲]	1.6 ± 0.37* [▲]

There were significant decrease of TP, Alb, and elevation of TC, TG, HDL, and LDL levels of the PAN group compared with that of the sham group on days 10 and 15 ($P < 0.05$). YQQRG could significantly reduce TG at day 10. At day 15, YQQRG increased plasma levels of TP and Alb and reduced TC, TG, and LDL levels (* $P < 0.05$ compared with sham group; [▲] $P < 0.05$ compared with PAN). (ALT: alanine transaminase; AST: aspartate aminotransferase; Cre: creatinine; BUN: blood urea nitrogen; TP: total protein; Alb: albumin; TC: total cholesterol; TG: triglycerides; HDL: high density lipoprotein; and LDL: low density lipoprotein.)

treated group, an effect equivalent to that of fosinopril (Figure 2).

3.2. YQQRG Attenuated Serum Alb Levels and Regulated Lipid Disorder without Apparent Liver and Kidney Adverse Effects. There was no significant difference among groups at day 3 for each of the biochemical parameters. There were significant decrease of TP, Alb, and elevation of TC, TG, HDL, and LDL levels of the PAN group compared with that of the sham group at days 10 and 15 ($P < 0.05$). YQQRG could significantly reduce TG at day 10, equivalent to that of the fosinopril. At day 15, YQQRG increased plasma levels of TP and Alb and reduced TC, TG, and LDL levels ($P < 0.05$ or $P < 0.01$), equivalent to that of the fosinopril. No

obvious differences were observed for ALT, AST, BUN, and Cre among each group at every time point (Table 1).

3.3. YQQRG Alleviated Kidney Morphological Lesions in PAN Rats. Pathological results revealed that there were no apparent pathological changes for both glomeruli and tubules at day 3. Together with elevated 24 h urinary protein, 10 and 15 days after PAN injection, there was apparent glomerular hypertrophy though no other pathologic lesions were seen in this study (Figure 3(a)). Typical tubular-interstitial lesions included protein casts, tubular protein reabsorption droplets, and interstitial inflammatory cells infiltration. Treatment with YQQRG and fosinopril appeared to alleviate such pathologic changes with similar degrees (Figure 3(b)).




FIGURE 2: YQQRG attenuated 24 h urinary protein in PAN induced nephrosis rats. 24 h urinary protein elevated significantly after PAN injection. YQQRG attenuated 24 h urinary protein excretion of PAN rats on days 9 and 14, an effect equivalent to that of the fosinopril. (Compared with sham group: * $P < 0.05$, ** $P < 0.01$, compared with PAN group: $\blacktriangle P < 0.05$, $\blacktriangle\blacktriangle P < 0.01$.)

Glomerular ultrastructure studies revealed obvious diffuse effacement of podocyte foot process, swelling of mitochondria, and disarrangement of microfilaments of the podocytes on day 3, a phenomenon that occurred before appearance of massive proteinuria. These lesions were worsened by day 10, with vacuolar degeneration of the podocyte cell body and universal effacement of foot process. However, on day 15, there was a trend of spontaneous attenuation, with less severe vacuolar degeneration and foot process effacement. Treatment with YQQRG significantly alleviated podocyte damage with significant reduction in foot process fusion and mitochondria swelling, equivalent to the effects of fosinopril (Figure 3(c)).

3.4. YQQRG Restored Nephritin, Podocin, and CD2AP Protein Expression and Downregulated mRNA Expression. To validate the protective effect of YQQRG on podocyte injury, the expressions of podocyte slit-diaphragm (SD) molecules nephritin, podocin, and CD2AP at mRNA and protein levels of renal cortex samples were detected by real-time PCR and western blot analysis. Localization of nephritin was detected by immunohistochemistry. Real-time PCR revealed that mRNA expressions of nephritin, podocin, and CD2AP were upregulated in PAN group compared with the sham group as of day 3. Treatment with YQQRG could significantly inhibit the mRNA expression of these genes on days 10 and 15 (Figures 4(a), 4(d), and 4(g)). Western blot revealed that compared with sham group, nephritin, podocin, and CD2AP expression in the PAN group was significantly decreased starting on day 3 ($P < 0.05$), and treatment with YQQRG restored podocin and nephritin expression on days 3, 10, and 15, however only on day 3 for CD2AP ($P < 0.05$) (Figures 4(b),

4(c), 4(e), 4(f), 4(h), and 4(i)). Nephritin expression detected by immunohistochemistry and data analysis revealed that podocyte nephritin expression was decreased as of day 3, and treatment with YQQRG could restore nephritin expression at every time point (Figure 5).

3.5. YQQRG Attenuated Podocyte Injury through Inhibition of VEGF-A Overexpression. To obtain insights into the regulatory mechanisms of YQQRG on SD molecule expression, we further investigated the effects of YQQRG on expression of VEGF-A. The mRNA expression of VEGF-A was significantly increased as of day 3, and YQQRG was able to inhibit its expression (Figure 6(a)). Western blot analysis revealed that VEGF-A expression was increased on day 3 and continued increasing until day 15. Treatment with YQQRG decreased VEGF-A levels on days 3, 10, and 15, an effect equivalent to that of fosinopril (Figures 6(b) and 6(c)).

4. Discussion

Proteinuria has been demonstrated to be related to adverse outcomes in patients with CKD. A high level of proteinuria increases the risks of myocardial infarction, kidney failure, and mortality [1]. Treatments for proteinuria currently include three kinds of therapeutic agents: glucocorticoids, cytotoxic drugs, and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs). Despite disease-specific functions of glucocorticoids and cytotoxic drugs, the most widely applied therapy for proteinuria is ACEI/ARBs. Clinical investigations have impressively demonstrated that ACEI/ARBs, used alone or combined, can relieve the severity of proteinuria, slow progressive loss of kidney function, independent of their blood pressure lowering effect [25]. However, ACEI/ARBs are not curative and most patients still have renal morbidity and mortality. Exploration for new therapies and their mechanisms, including traditional Chinese medicine, is a constant topic in this field. YQQRG is a widely used formula in Guang'anmen Hospital, with demonstrated antiproteinuric and antisclerotic effects [21, 22]. The current study investigates the effect of YQQRG on podocyte injury and VEGF expression in the kidney tissue of PAN model, with fosinopril, an ACEI, as control for the treatment of proteinuria.

PAN model is a classic model to study the mechanism of proteinuria and podocytopathy, in which PAN specifically injures the GFB and manifests as podocyte foot process effacement, depletion of podocyte number, and direct damage to the negative-charged barrier [26]. Podocyte apoptosis is an early and important manifestation in PAN nephrosis, with apparent cell membrane inversion and mitochondrial membrane potential depolarization [27]. Estrogen receptor α and nestin are demonstrated to protect podocyte from apoptosis [27, 28]. Shibata et al. reported that 12 h after a single intravenous injection of PAN (10 mg/100 g), there was reduced staining of nephritin detected by immunofluorescence and significant decrease of nephritin mRNA expression in the glomeruli [29]. Similar results were seen 5 days




FIGURE 3: YQQRG alleviated kidney morphologic lesions in PAN rats. (a) Rat in PAN group exhibited glomerular hypertrophy on days 10 and 15; no other pathological lesions were seen (PAS, magnification $\times 400$, scale bar = $50 \mu\text{m}$). (b) Extension of tubules with protein casts; interstitial inflammatory cell infiltration was obvious in the PAN group on days 10 and 15. YQQRG attenuated such lesions (PAS, magnification $\times 400$, scale bar = $50 \mu\text{m}$). (c) Diffuse effacement of podocyte foot process, mitochondria swelling, and disarrangement of microfilaments of podocytes occurred on day 3 and worsened on day 10. However, there was a trend of spontaneous attenuation on day 15. YQQRG protected against podocyte injury (magnification $\times 10000$, scale bar = $2 \mu\text{m}$).

after PAN administration at the same dosage [30]. However, there are discrepancies regarding mRNA expression of nephrin and podocin. Subcutaneous injection of PAN (120 mg/kg) induced decreased protein expression of nephrin and podocin from days 3 to 5 after injection, a time that

albuminuria begins to develop. However, nephrin mRNA level was significantly enhanced on days 2 and 3 after PAN injection, normalized on day 4 and decreased on day 5. Podocin mRNA level was not significantly changed from 1 to 5 days after PAN injection [31]. Research by Han et al.





FIGURE 4: YQQRG downregulated nephrin, podocin, and CD2AP mRNA expression and restored their protein expression. Nephrin podocin and CD2AP mRNA expression was upregulated about 2-fold in PAN group compared with sham group on day 3 (a) and upregulated about 3-fold on days 10 and 15 (d and g). Treatment with YQQRG significantly inhibited the mRNA expression of these genes on days 10 and 15 (a, d, and g). Western blot revealed that compared with sham group, nephrin, podocin, and CD2AP expression in the PAN group was significantly decreased starting on day 3 ($P < 0.05$), and treatment with YQQRG restored podocin and nephrin expression on days 3, 10, and 15, however only on day 3 for CD2AP ($P < 0.05$) (b, c, e, f, h, i). (Compared with sham group: * $P < 0.05$, ** $P < 0.01$, compared with PAN group: ▲ $P < 0.05$, ▲▲ $P < 0.01$.)


revealed that mRNA expression of nephrin and podocin was significantly lower on day 1 and recovered (for nephrin) or increased (for podocin) on day 28 [32]. Discrepancies between these studies are difficult to explain and may be due to different administration of PAN, animal strain, or different time points of observation. In our study, we dynamically observed the 24 h urinary protein, pathological changes, and alterations of nephrin, podocin, and CD2AP expression in the PAN model. 24 h urinary protein increased after PAN injection and peaked at 10 days. Treatment with YQQRG

significantly decreased urinary protein and elevated serum albumin. Ultrastructural changes occurred prior to massive proteinuria, including diffuse podocyte foot process effacement, swelling of the mitochondria, and disarrangement of microfilaments. YQQRG attenuated these pathological changes, exhibiting a protective effect on GFB structure, an effect equivalent to that of fosinopril.

In order to study the molecular mechanism of YQQRG on GFB function, we further studied the SD related molecules nephrin, podocin, and CD2AP. The mRNA expressions of



(a)



(b)

FIGURE 5: YQQRG restored podocyte nephrin expression. Immunohistochemistry and semiquantitative analysis revealed that nephrin expression was decreased at day 3 and further declined at days 10 and 15. YQQRG could restore nephrin expression at every time point, equivalent to that of fosinopril (magnification $\times 400$, scale bar = $50 \mu\text{m}$).




FIGURE 6: YQQRG decreased VEGF-A expression. VEGF-A level was increased early on day 3 and continued to day 15. Treatment with YQQRG attenuated VEGF expression. (Compared with sham group: * $P < 0.05$, ** $P < 0.01$, compared with PAN group: [▲] $P < 0.05$, ^{▲▲} $P < 0.01$.)

nephrin, CD2AP, and podocin were upregulated in the PAN group compared with the sham group as of day 3. Treatment with YQQRG significantly inhibited mRNA expression of these genes on days 10 and 15. However, the protein levels of nephrin, podocin, and CD2AP were decreased early on day 3, and treatment restored their expression, a phenomenon that seems contradictory. A possible explanation is that the alterations of SD molecules in the PAN model are at the translation stage rather than the transcription stage. In passive Heymann nephritis, a discrepancy of nephrin mRNA upregulation and decrease in protein was also detected, due to suppressed translation of nephrin [33]. Human nephrin has 10 potential N-glycosylation sites in its amino acid sequence [34]. It has been reported that N-glycosylation of nephrin plays a crucial role in molecular folding and is critical for plasma membrane localization. In PAN nephrosis, non- or subglycosylated nephrin undergoes unfolded protein response (UPR), and nonglycosylated and incorrectly folded nephrin is retained in the endoplasmic reticulum and is subsequently transported to the cytoplasm for ubiquitination

and degradation by proteasomes [19, 35]. The upregulation of nephrin mRNA may be a negative feedback reaction in the defect of posttranslational modification.

VEGF-A is a pleiotropic growth factor essential for endothelial cell differentiation, survival, proliferation, and migration. Podocytes are the major source of VEGF-A in the glomeruli. VEGF-A acts as chemoattractant for endothelial cells, guiding their migration towards developing into nephron during kidney organogenesis [36]. VEGF-A is essential for maintenance of the fenestrated phenotype for glomerular endothelial cells. VEGF-A also interacts with podocyte slit-diaphragm molecules to regulate the integrity of the GFB. Studies have shown that patients who underwent chemotherapy with anti-VEGF or receptor tyrosine kinase inhibitors experienced proteinuria, podocyturia, hypertension, and glomerular thrombotic microangiopathy, indicating damage to the GFB [37–39]. In cultured podocytes, VEGF-A induces podocin upregulation, increases podocin-CD2AP interaction, and downregulates and stimulates nephrin phosphorylation in a dose-dependent

manner [18]. Induction of podocyte VEGF-A overexpression causes reversible nephrin downregulation and phosphorylation, associated with foot process effacement and proteinuria [20, 38]. Podocyte derived VEGF functions as an important “cross-talk” protein among the three components of GFB in developing and mature glomeruli. An early study by Fan et al. found a downregulation of VEGF and its receptors in the PAN model [40]. However, increasing evidence confirms that in PAN model, as well as in passive Heymann nephrosis and diabetic nephropathy, upregulation of VEGF and its receptors VEGFR1 and VEGFR2 is correlated with severity of proteinuria [41, 42]. In human biopsy specimens, VEGF and its receptor expression as well as VEGF-VEGFR2 complex, without any exception, were increased in the podocyte, indicating an autocrine loop in diseased podocytes [43]. PAN model treated with anti-VEGF serum for the first 5 days of induction of PAN nephrosis exhibited no effect on proteinuria and glomerular filtration rate, a result consistent with VEGF165 aptamer treatment for the PAN model [42, 44]. Experiments using *in vivo* and *in vitro* transgenic models demonstrated that podocyte derived VEGF has a self-protective autocrine function against PAN induced podocyte injury [45]. All these results indicate that VEGF-A and VEGFR expressions probably impact proteinuria in a less direct way, the altered VEGF signaling may be a protective response. In our study, VEGF-A expression was increased on day 3 after PAN injection, simultaneous with nephrin downregulation and podocyte damage. A possible mechanism may be that the direct podocyte toxin of PAN caused suppression of SD molecules. Subsequently, podocyte enhanced VEGF-A expression in a self-protective way. However, VEGF-A overexpression exacerbated podocyte injury and caused further damage. There were also enhanced expressions of both VEGFR1 and VEGFR2 that we were unable to identify the specific source of (data not shown). Thus, YQQRG appears to restore SD function through inhibition of VEGF and upregulation of nephrin, podocin, and CD2AP.

YQQRG is comprised of 12 active constituents. Astragalus (*Radix Astragali Mongolici*) has been demonstrated to decrease the overexpression of VEGF induced by high glucose in Müller cells [46]. Astragalus saponins have also been found to inhibit human gastric adenocarcinoma cell proliferation and invasion by downregulation of the proangiogenic protein VEGF as well as the metastatic proteins metalloproteinase-2 (MMP-2) and MMP-9 [47]. In the complement membranous attack complex induced podocyte injury model, astragaloside IV (AS-IV) restores podocyte morphology and cytoskeleton loss in a dose- and time-dependent manner. Furthermore, AS-IV was able to reduce phosphorylation of JNK and ERK1/2 induced by complement membranous attack complex [48]. In streptozotocin induced rat diabetic nephropathy model, AS-IV ameliorated albuminuria, renal histopathology, and podocyte foot process effacement and inhibited kidney expression and serum levels of nuclear factors- κ B (NF- κ B), tumor necrosis factor- α (TNF- α), monocyte chemotactic protein-1 (MCP-1), and intercellular cell adhesion molecule-1 (ICAM-1) [49]. Astragalus has been reported to inhibit angiotensin converting enzyme (ACE) activity *in vitro* [50]. Nevertheless, there are

reports that renal local angiotensin II (Ang II) is not affected by combination of Astragalus and Angelica (AA). The AA retarded the progression of renal fibrosis and renal function deterioration, which is similar to the effect of ACEI. These renoprotective effects were not via inhibitory renal Ang II, whereas they were associated with suppression of TGF- β 1 and osteopontin overexpression, reduction of both infiltration of monocyte/macrophage, and activation of renal intrinsic cells [51]. The actions of a single component and mixture of a formula are quite different. The actions of formula may be related to multiple pathways and mechanisms. Ethanol extract of honeysuckle flower (*Flos Lonicerae*) ameliorates kidney injury in diabetic rats, reduces macrophage and T cell infiltration, and attenuates expression of proinflammatory cytokines, by downregulation of p38-mitogen-activated protein kinase in diabetic rats [52]. *Hedyotis Diffusa Willd* (HDW) is a herbal medicinal widely used in the treatment of cancer in China. Recent studies indicate that ethanol extract of HDW inhibits the proliferation, migration, and tube formation of human umbilical vein endothelial cells in a dose- and time-dependent manner [53]. In the colorectal cancer mouse xenograft model, ethanol extract of HDW was found to inhibit sonic hedgehog signaling pathway dependent VEGF-A and VEGFR2 expression [54]. Japanese dioscorea rhizome has been demonstrated to have immune regulatory, antiviral, and antibacterial effects. Its active components are protodioscin and dioscin. Protodioscin was reported to have antihyperlipidemic effect [55]. In lipopolysaccharide-stimulated rat mesangial cells, dioscin inhibited mesangial cell proliferation and downregulated expressions of Wnt4, β -catenin, and TGF- β 1 in a dose- and time-dependent manner [56]. The renal protective effects of YQQRG in PAN rats may be due to the aforementioned modes of the active constituents in the formula.

In conclusion, our data suggest that YQQRG may possess renal protective effect in the proteinuric state via restoration of renal glomerular filtration barrier and by inhibition of VEGF expression. These results indicate that YQQRG is an attractive and suitable alternative therapy for treating proteinuria. Further mechanism studies are being undertaken.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors' Contribution

Yongli Zhan, Liping Yang, and Yumin Wen contributed equally to this work.

Acknowledgments

This work was supported by the National Nature Science Foundation of China (nos. 81072971 and 81102588). The authors thank Nissi S. Wang, M.S., for editorial assistance with this paper.

References

- [1] B. R. Hemmelgarn, B. J. Manns, A. Lloyd et al., "Relation between kidney function, proteinuria, and adverse outcomes," *Journal of the American Medical Association*, vol. 303, no. 5, pp. 423–429, 2010.
- [2] J. E. Toblli, P. Bevione, F. Di Gennaro, L. Madalena, G. Cao, and M. Angerosa, "Understanding the mechanisms of proteinuria: therapeutic implications," *International Journal of Nephrology*, vol. 2012, Article ID 546039, 13 pages, 2012.
- [3] P. W. Mathieson, "Update on the podocyte," *Current Opinion in Nephrology and Hypertension*, vol. 18, no. 3, pp. 206–211, 2009.
- [4] H. Pavenstadt, W. Kriz, and M. Kretzler, "Cell biology of the glomerular podocyte," *Physiological Reviews*, vol. 83, no. 1, pp. 253–307, 2003.
- [5] P. Aaltonen and H. Holthofer, "The nephrin-based slit diaphragm: new insight into the signalling platform identifies targets for therapy," *Nephrology Dialysis Transplantation*, vol. 22, no. 12, pp. 3408–3410, 2007.
- [6] A. M. Kuusniemi, J. Merenmies, A. T. Lahdenkari et al., "Glomerular sclerosis in kidneys with congenital nephrotic syndrome (NPHS1)," *Kidney International*, vol. 70, no. 8, pp. 1423–1431, 2006.
- [7] J. Patrakka, M. Kestila, J. Wartiovaara et al., "Congenital nephrotic syndrome (NPHS1): features resulting from different mutations in Finnish patients," *Kidney International*, vol. 58, no. 3, pp. 972–980, 2000.
- [8] J. M. Kim, H. Wu, G. Green et al., "CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility," *Science*, vol. 300, no. 5623, pp. 1298–1300, 2003.
- [9] G. Wolf and R. A. Stahl, "CD2-associated protein and glomerular disease," *The Lancet*, vol. 362, no. 9397, pp. 1746–1748, 2003.
- [10] S. Yaddanapudi, M. M. Altintas, A. D. Kistler et al., "CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival," *Journal of Clinical Investigation*, vol. 121, no. 10, pp. 3965–3980, 2011.
- [11] H. G. Kang, K. H. Paik, H. Y. Cho et al., "Transcriptome analysis of the response of cultured murine podocytes to puromycin aminonucleoside," *Nephron—Experimental Nephrology*, vol. 115, no. 1, pp. e1–e8, 2010.
- [12] T. Inoue, E. Yaoita, H. Kurihara et al., "FAT is a component of glomerular slit diaphragms," *Kidney International*, vol. 59, no. 3, pp. 1003–1012, 2001.
- [13] E. Schnabel, J. M. Anderson, and M. G. Farquhar, "The tight junction protein ZO-1 is concentrated along slit diaphragms of the glomerular epithelium," *Journal of Cell Biology*, vol. 111, no. 3, pp. 1255–1263, 1990.
- [14] R. Doyonnas, D. B. Kershaw, C. Duhme et al., "Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin," *The Journal of Experimental Medicine*, vol. 194, no. 1, pp. 13–27, 2001.
- [15] V. Eremina, H. J. Baelde, and S. E. Quaggin, "Role of the VEGF-A signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier," *Nephron Physiology*, vol. 106, no. 2, pp. p32–p37, 2007.
- [16] F. Guan, G. Villegas, J. Teichman, P. Mundel, and A. Tufro, "Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP," *The American Journal of Physiology: Renal Physiology*, vol. 291, no. 2, pp. F422–F428, 2006.
- [17] K. Sison, V. Eremina, H. Baelde et al., "Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling," *Journal of the American Society of Nephrology*, vol. 21, no. 10, pp. 1691–1701, 2010.
- [18] C. Bertuccio, D. Veron, P. K. Aggarwal, L. Holzman, and A. Tufro, "Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes," *Journal of Biological Chemistry*, vol. 286, no. 46, pp. 39933–39944, 2011.
- [19] A. Nakajo, J. Khoshnoodi, H. Takenaka et al., "Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance," *Journal of the American Society of Nephrology*, vol. 18, no. 9, pp. 2554–2564, 2007.
- [20] D. Veron, K. Reidy, A. Marlier et al., "Induction of podocyte VEGF164 overexpression at different stages of development causes congenital nephrosis or steroid-resistant nephrotic syndrome," *The American Journal of Pathology*, vol. 177, no. 5, pp. 2225–2233, 2010.
- [21] Y. Zhan and X. Dai, "Treatment of 30 cases with chronic nephritis with replenishing qi, removing blood stasis, clearing heat and toxin methods," *Journal of Traditional Chinese Medicine*, vol. 44, no. 12, pp. 922–924, 2003.
- [22] Y. Zhan, X. Dai, X. Li, S. Li, and X. Rao, "Renoprotective effect of Yiqiqingre extract in Adriamycin nephritic rats," *Chinese Journal of Integrated Traditional and Western Nephrology*, vol. 4, no. 3, pp. 135–138, 2003.
- [23] H. Zhang, T. Zhao, Y. Gong et al., "Attenuation of diabetic nephropathy by Chaihuang-Yishen granule through anti-inflammatory mechanism in streptozotocin-induced rat model of diabetes," *Journal of Ethnopharmacology*, vol. 151, no. 1, pp. 556–564, 2014.
- [24] T. Schmittgen and K. Livak, "Analyzing real-time PCR data by the comparative C(T) method," *Nature Protocols*, vol. 3, no. 6, pp. 1101–1108, 2008.
- [25] L. Tylicki, S. Lizakowski, and B. Rutkowski, "Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions," *Journal of Nephrology*, vol. 25, no. 6, pp. 900–910, 2012.
- [26] S. Inokuchi, I. Shirato, N. Kobayashi, H. Koide, Y. Tomino, and T. Sakai, "Re-evaluation of foot process effacement in acute puromycin aminonucleoside nephrosis," *Kidney International*, vol. 50, no. 4, pp. 1278–1287, 1996.
- [27] S. Kummer, S. Jeruschke, L. van Wegerich et al., "Estrogen receptor alpha expression in podocytes mediates protection against apoptosis in-vitro and in-vivo," *PLoS ONE*, vol. 6, no. 11, Article ID e27457, 2011.
- [28] D. Wen, L. You, Q. Zhang et al., "Upregulation of nestin protects podocytes from apoptosis induced by puromycin aminonucleoside," *The American Journal of Nephrology*, vol. 34, no. 5, pp. 423–434, 2011.
- [29] S. Shibata, M. Nagase, and T. Fujita, "Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling," *Journal of the American Society of Nephrology*, vol. 17, no. 3, pp. 754–764, 2006.
- [30] A. Suzuki, T. Ito, E. Imai et al., "Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats," *Journal of the American Society of Nephrology*, vol. 14, no. 4, pp. 981–991, 2003.
- [31] M. Hosoyamada, K. Yan, Y. Nishibori et al., "Nephrin and podocin expression around the onset of puromycin aminonucleoside nephrosis," *Journal of Pharmacological Sciences*, vol. 97, no. 2, pp. 234–241, 2005.
- [32] G. D. Han, K. Suzuki, H. Koike et al., "IFN-inducible protein-10 plays a pivotal role in maintaining slit-diaphragm function by

- regulating podocyte cell-cycle balance,” *Journal of the American Society of Nephrology*, vol. 17, no. 2, pp. 442–453, 2006.
- [33] S. Stratakis, K. Stylianou, I. Petrakis et al., “Rapamycin ameliorates proteinuria and restores nephrin and podocin expression in experimental membranous nephropathy,” *Clinical and Developmental Immunology*, vol. 2013, Article ID 941893, 8 pages, 2013.
- [34] M. Kestila, U. Lenkkeri, M. Mannikko et al., “Positionally cloned gene for a novel glomerular protein—nephrin—is mutated in congenital nephrotic syndrome,” *Molecular Cell*, vol. 1, no. 4, pp. 575–582, 1998.
- [35] K. Yan, J. Khoshnoodi, V. Ruotsalainen, and K. Tryggvason, “N-linked glycosylation is critical for the plasma membrane localization of nephrin,” *Journal of the American Society of Nephrology*, vol. 13, no. 5, pp. 1385–1389, 2002.
- [36] A. Tufro, “VEGF spatially directs angiogenesis during metanephric development in vitro,” *Developmental Biology*, vol. 227, no. 2, pp. 558–566, 2000.
- [37] T. V. Patel, J. A. Morgan, G. D. Demetri et al., “A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib,” *Journal of the National Cancer Institute*, vol. 100, no. 4, pp. 282–284, 2008.
- [38] D. Veron, K. J. Reidy, C. Bertuccio et al., “Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease,” *Kidney International*, vol. 77, no. 11, pp. 989–999, 2010.
- [39] J. C. Yang, L. Haworth, R. M. Sherry et al., “A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer,” *The New England Journal of Medicine*, vol. 349, no. 5, pp. 427–434, 2003.
- [40] L. Fan, T. Wakayama, S. Yokoyama, O. Amano, and S. Iseki, “Downregulation of vascular endothelial growth factor and its receptors in the kidney in rats with puromycin aminonucleoside nephrosis,” *Nephron*, vol. 90, no. 1, pp. 95–102, 2002.
- [41] G. A. Sivaskandarajah, M. Jeansson, Y. Maezawa, V. Eremina, H. J. Baelde, and S. E. Quaggin, “Vegfa protects the glomerular microvasculature in diabetes,” *Diabetes*, vol. 61, no. 11, pp. 2958–2966, 2012.
- [42] J. Kanellis, V. Levidiotis, T. Khong et al., “A study of VEGF and its receptors in two rat models of proteinuria,” *Nephron Physiology*, vol. 96, no. 1, pp. P26–P36, 2004.
- [43] B. Hohenstein, M. Colin, C. Foellmer et al., “Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans,” *Nephrology Dialysis Transplantation*, vol. 25, no. 10, pp. 3170–3180, 2010.
- [44] T. Ostendorf, U. Kunter, F. Eitner et al., “VEGF(165) mediates glomerular endothelial repair,” *Journal of Clinical Investigation*, vol. 104, no. 7, pp. 913–923, 1999.
- [45] J. Ma, T. Matsusaka, H. C. Yang et al., “Induction of podocyte-derived VEGF ameliorates podocyte injury and subsequent abnormal glomerular development caused by puromycin aminonucleoside,” *Pediatric Research*, vol. 70, no. 1, pp. 83–89, 2011.
- [46] M. Ke, X. Q. Hu, J. Ouyang, B. Dai, and Y. Xu, “The effect of astragalins on the VEGF production of cultured Muller cells under high glucose conditions,” *Bio-Medical Materials and Engineering*, vol. 22, no. 1–3, pp. 113–119, 2012.
- [47] K. K. Auyeung, P. K. Woo, P. C. Law, and J. K. Ko, “Astragalus saponins modulate cell invasiveness and angiogenesis in human gastric adenocarcinoma cells,” *Journal of Ethnopharmacology*, vol. 141, no. 2, pp. 635–641, 2012.
- [48] R. Zheng, Y. Deng, Y. Chen et al., “Astragaloside IV attenuates complement membranous attack complex induced podocyte injury through the MAPK pathway,” *Phytotherapy Research*, vol. 26, no. 6, pp. 892–898, 2012.
- [49] D. Gui, J. Huang, Y. Guo et al., “Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-kappaB-mediated inflammatory genes expression,” *Cytokine*, vol. 61, no. 3, pp. 970–977, 2013.
- [50] G. S. Patten, M. Y. Abeywardena, and L. E. Bennett, “Inhibition of angiotensin converting enzyme, angiotensin II receptor blocking and blood pressure lowering bioactivity across plant families,” *Critical Reviews in Food Science and Nutrition*, 2013.
- [51] H. Y. Wang, J. Z. Li, J. S. Pan et al., “The effect of Astragali and Angelica on nephrotic syndrome and its mechanisms of action,” *Journal of Beijing Medical University*, vol. 34, no. 5, pp. 542–552, 2002.
- [52] T. F. Zeng, S. S. Liou, C. J. Chang, and I. M. Liu, “The ethanol extract of *Lonicera japonica* (Japanese honeysuckle) attenuates diabetic nephropathy by inhibiting p-38 MAPK activity in streptozotocin-induced diabetic rats,” *Planta Medica*, vol. 80, no. 2–3, pp. 121–129, 2014.
- [53] J. Lin, L. Wei, W. Xu, Z. Hong, X. Liu, and J. Peng, “Effect of *Hedyotis Diffusa* Willd extract on tumor angiogenesis,” *Molecular Medicine Reports*, vol. 4, no. 6, pp. 1283–1288, 2011.
- [54] J. Lin, L. Wei, A. Shen et al., “*Hedyotis diffusa* Willd extract suppresses Sonic hedgehog signaling leading to the inhibition of colorectal cancer angiogenesis,” *International Journal of Oncology*, vol. 42, no. 2, pp. 651–656, 2013.
- [55] T. Wang, R. C. Choi, J. Li et al., “Antihyperlipidemic effect of protodioscin, an active ingredient isolated from the rhizomes of *dioscorea nipponica*,” *Planta Medica*, vol. 76, no. 15, pp. 1642–1646, 2010.
- [56] X. Sun, L. Yang, Y. Zhan et al., “Dioscin ameliorates lipopolysaccharide-stimulated rat mesangial cell proliferation through suppressing wnt pathway and TGF- β 1 expression,” *China Journal of Traditional Chinese Medicine and Pharmacy*, vol. 29, no. 3, pp. 871–874, 2014.